Table 2.
Studies assessing the use of standardised uptake value (SUV) in predicting outcomes in diffuse large B cell lymphoma (DLBCL) and Hodgkin lymphoma (HL)
| First author | Year | Type | Study type | Patient no. | Stage | Treatment | Events (follow-up cut-off) | SUV Type | Cut-off value | Predictive univariate analysis HR (95% CI) |
Predictive multivariate analysis HR (95% CI), parameters included in multivariate analysis |
|||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| I/II | III/IV | PFS | OS | PFS | OS | |||||||||
| Aide [10] | 2020 | DLBCL | R | 132 (80:20 training/validation) | NR | NR | R-CHOP, R-ACVBP |
Relapse/death: 102 (2-year) |
SUVmax | 32.21 | NS | NR | NR | NR |
| Albano [13]a | 2020 | HL (Aged 65–92) | R | 123 | 36 | 87 | ABVD, BEACOPP, R-CHOP, ± RT, RT |
Relapse: 51 Died: 37 (no defined cut-off) |
L-L SUV R | 9.3 | 0.447 (0.237–0.748) | 0.526 (0.261–0.992) | 0.228 (0.049–0.765) | 0.200 (0.033–0.353) |
| L-BP SUV R | 6.4 | 0.469 (0.229–0.774) | 0.523 (0.241–0.983) | 0.354 (0.069–0.989) | 0.555 (0.201–1.002) | |||||||||
| Ceriani [16] | 2020 | DLBCL | R | 141 – Testing | 61 | 80 | R-CHOP ± RT | NR | Max | 20 | NS | NS | NR | NR |
| 113 -Validation | 49 | 64 | R-CHOP ± RT | NR | Max | 31 | NS | NS | NR | NR | ||||
| Zhang [48] | 2019 | DLBCL | R | 85 | 32 | 53 | R-CHOP/R-CHOP like |
Relapse/Died:23 (3-year) |
Max | NR – AUC 0.573 | NR | NR | NR | NR |
| Akhtari [12] | 2018 | HL | R | 267 | 205 | 62 | ABVD ± RT/othera |
Relapsed/refractory: 27 (5-year) |
Max | NR | NS | NR | NR | NR |
| Cottereau [21] | 2018 | HL | R | 258 | 258 | 0 | ABVD ± RT |
PFS: 27 events OS: 12 (5-year) |
Max | NR | NS | NS | NR | NR |
| Toledano [45] | 2018 | DLBCL | R | 114 | 26 | 88 | R-CHOP/R-CHOP like |
Relapse: 52 Died: 43 (5-year) |
Max | NR | NS | NS | NR | NR |
| Angelopoulou [14] | 2017 | HL | R | 162 | 76 | 86 | ABVD ± BEACOPP, ± RT |
PFS: 81% OS: 93% (5-year) |
Max | <9, 9–18, >18 | 93%, 81%, 58% | NR | NR | NR |
| Chang [17] | 2017 | DLBCL | R | 118 | 48 | 70 | R-CHOP |
Relapse: 55 Died: 49 (5-year) |
Max | 18.8 | NS | NS | NR | NR |
| Chang [18] | 2017 | DLBCL | R | 70 | 35 | 35 | R-CHOP | NR | Tumour Max | 19 | 2.76 (1.05–7.61) | NS | 3.27 (1.11–9.60) | NS |
| Sternal Max | 1.6 | NS | 2.34 (1.01–5.44) | NS | 2.62 (1.10–6.28 | |||||||||
| Cottereau [22] | 2016 | DLBCL | R | 81 | 16 | 65 | R-CHOP, R-ACVBP |
Relapse: 34 (5-year) |
Max | NR | NS | NS | NR | NR |
| Huang [26] | 2016 | DLBCL | R | 140 | 62 | 78 | R-CHOP/CHOP |
PFS: 73.8% OS: 86.1% (30-month) |
Max | 9 | 7.2 (2.201–23.631) | 11.4 (1.514–86.350 0.018) | 4.7 (1.429–16.022 0.011) | NS |
| Mikhaeel [36] | 2016 | DLBCL | R | 147 | 46 | 101 | R-CHOP |
PFS: 65.4% OS: 73.7% (5-year) |
Max | Split into tertiles | NS | NS | NR | NR |
| Xie [47] | 2016 | DLBCL | R | 60 | 12 | 48 | R-CHOP |
Relapse: 17 Died: 3 (40-month) |
Max | NR | NS | NR | NS | NR |
| Zhou [49] | 2016 | DLBCL | R | 91 | 34 | 57 | R-CHOP |
Relapse: 37 Died: 11 (5-year) |
Max |
PFS – 19 OS – 15.8 |
NS | NS | NR | NR |
| Adams [9] | 2015 | DLBCL | R | 73 | 11 | 62 | R-CHOP |
Relapse: 27 Death: 24 (No defined cut-off) |
Max | NR | NS | NS | NR | NR |
| Jagadeesh [28] | 2015 | DLBCL | R | 89 | 0 | 89 | R-CHOP/R + other |
LR: 50% (5-year) |
Max | 15 | NS for LR | NR | NS for LR | NR |
| Kwon [32] | 2015 | DLBCL | R | 92 | 54 | 38 | R-CHOP |
Relapse: 33 Died: 3 (No defined cut-off) |
Max | 10.5 | 4.31 (1.03–18.1) | NR | NS | NR |
| Gallicchio [25] | 2014 | DLBCL | R | 52 | 26 | 26 | R-CHOP, R-COMP |
Relapse: 15 Died: 2 (18 month) |
Max | 13.5 | 0.13 (0.04–0.46) | NR | NR | NR |
| Esfahani [24] | 2013 | DLBCL | R | 20 | 8 | 12 | R-CHOP |
Relapse: 6 (No defined cut-off) |
Max | 13.84 | NS | NR | NR | NR |
| Mean | 6.44 | NS | NR | NR | NR | |||||||||
| Kim [31] | 2013 | DLBCL | R | 140 | 77 | 63 | R-CHOP |
Relapse: 21 Died: 16 (2-year) |
Max | 16.4 | NS | NS | NR | NR |
| Lanic [33] | 2012 | DLBCL | R | 57 | NR | NR | R-CHOP, intensified R-CHOP |
NR (2-year) |
Max | NR | NS | NS | NR | NR |
| Park [39] | 2012 | DLBCL | R | 100 | 55 | 45 | R-CHOP | NR | Max | NR | NS | NS | NR | NR |
| Sum | NR | 1.011 (1.002–1.020) | 1.016 (1.006–1.026) | NR | NR | |||||||||
| Tseng [46] | 2012 | HL | R | 30 | 11 | 19 | Standford V, ABVD, VAMP, BEACOPP |
Relapse =6 (4-year) |
Max | NR | NS | NS | NR | NR |
| Mean | NR | NS | NS | NR | NR | |||||||||
| Chihara [19] | 2011 | DLBCL | R | 110 | 65 | 45 | R-CHOP ± RT |
PFS: 75% OS: 84% (3-year) |
Max | 30 | Sig. | Sig. | HR6.74 | NS |
R retrospective; NR not reported; NS not significant; Sig. significant; HR hazard ratio; CI confidence interval; PFS progressive free survival; OS overall survival; R-CHOP rituximab cyclophosphamide, doxorubicin hydrochloride, vincristine (Oncovin) and prednisolone; R-ACVBP Rituximab, Doxorubicin, Cyclophosphamide, Vindesine, Bleomycin, prednisolone; R-COMP prednisolone, Cyclophosphamide, Vincristine, Myocet and Rituximab; RT radiotherapy; ABVD doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine; eBEACOPP escalated dose bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), procarbazine and prednisone; VAMP vincristine, doxorubicin hydrochloride, methotrexate, prednisolone
aThe HRs presented as presented in the study but are inverse to the other HRs within the table